Bioxytran Interview on the Rising Development Convention
– Wednesday, January 25, 2023 10:50 am –11:20am EST
– Dialogue of the Biotech Showcase Convention
BOSTON, MASSACHUSETTS, Jan. 24, 2023 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (OTCQB: BIXT) (the “Firm”), a medical stage biotechnology firm creating oral and intravenous medicine to deal with COVID-19 and different viral inflicting illnesses introduced that Bioxtran CMO Michael Sheikh might be discussing his attendance on the Biotech Showcase on the Rising Development Convention on January 25, 2023 at 10:50am EST. Buyers are inspired to preregister to make sure you’ll be able to attend the convention and obtain any updates which can be launched.
Occasion: Rising Development Convention
Date: January 25, 2023
Registration: https://goto.webcasts.com/starthere.jsp?ei=1575092&tp_key=9111d280ed&sti=bixt
Time: 10:50am – 11:20am EST
If attendees will not be in a position to be part of the occasion dwell on the day of the convention, an archived webcast may also be made obtainable on EmergingGrowth.com and we may also launch a hyperlink to that after the occasion.
In regards to the Rising Development Convention
The Rising Development convention is an efficient manner for public corporations to current and talk their new merchandise, providers and different main bulletins to the funding neighborhood from the comfort of their workplace, in a time environment friendly method.
The Convention focus and protection contains corporations in a variety of development sectors, with sturdy administration groups, progressive merchandise & providers, centered technique, execution, and the general potential for long run development. Its viewers contains probably tens of 1000’s of Particular person and Institutional traders, in addition to Funding advisors and analysts.
All periods might be performed by way of video webcasts and can happen within the Jap time zone.
About Bioxytran, Inc.
Bioxytran, Inc. is a medical stage biotechnology firm creating novel therapies concentrating on the remedy of great unmet medical wants in virology, degenerative illness, and hypoxia. The main drug candidate, Prolectin-M, is a brand new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant illnesses. Bioxytran’s different improvement applications are for pulmonary fibrosis and stroke remedy. Extra info could be discovered at www.bioxytraninc.com
Investor Relations
Michael Sheikh
509-991-0245
[email protected]
Ahead-Trying Statements
This press launch contains forward-looking statements as outlined underneath federal legislation, together with these associated to the efficiency of know-how described on this press launch. These forward-looking statements are typically recognized by the phrases “imagine,” “count on,” “anticipate,” “estimate,” “intend,” “plan,” and comparable expressions, though not all forward-looking statements include these figuring out phrases. Such statements are topic to important dangers, assumptions and uncertainties. Identified materials components that would trigger Bioxytran’s precise outcomes to vary materially from the outcomes contemplated by such forward-looking statements are described within the forward-looking statements and threat components within the Firm’s Annual Report on Type 10-Ok for the fiscal 12 months ended December 31, 2021 and people threat components set forth from time-to-time in different filings with the Securities and Alternate Fee. Bioxytran undertakes no obligation to appropriate or replace any forward-looking assertion, whether or not on account of new info, future occasions, or in any other case, besides to the extent required underneath federal securities legal guidelines.
